# Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell Carcinomas

> **NCT04570683** · EARLY_PHASE1 · UNKNOWN · sponsor: **Bispebjerg Hospital** · enrollment: 30 (estimated)

## Conditions studied

- BCC - Basal Cell Carcinoma
- Immune Response
- Immunotherapy
- Ablative Fractionated Laser

## Interventions

- **DRUG:** Nivolumab 10 MG/ML
- **DEVICE:** Ablative fractionated laser

## Key facts

- **NCT ID:** NCT04570683
- **Lead sponsor:** Bispebjerg Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-01-27
- **Primary completion:** 2021-09
- **Final completion:** 2021-11
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2020-09-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04570683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04570683, "Laser Immunotherapy With and Without Topical Anti-PD1 in Basal Cell Carcinomas". Retrieved via AI Analytics 2026-05-30 from https://api.ai-analytics.org/clinical/NCT04570683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*